A 54 Week Treatment, Randomized, Multi Center, Double Blind, Placebo Controlled Study to Assess the Safety and Efficacy of NEBIDO [testosterone undecanoate] 1000 mg (4 ml) in Elderly Men With Symptomatic Late Onset Hypogonadism (SLOH).
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 26 Nov 2012
At a glance
- Drugs Testosterone undecanoate (Primary)
- Indications Hypogonadism
- Focus Pharmacodynamics
- Sponsors Bayer
- 31 Aug 2018 Biomarkers information updated
- 16 Nov 2011 Additional locations (England, Italy, Latvia, Poland, Russia, United Kingdom) added as reported by ClinicalTrials.gov.
- 22 Nov 2010 Trial location (Germany) identified as reported by ClinicalTrials.gov.